Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 781.40K | 781.40K | 744.30K | 352.60K | 563.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.45M | 1.45M | 1.72M | 1.04M | 1.54M |
| Operating Income | -1.45M | -1.45M | -1.72M | -1.04M | -1.54M |
| Income Before Tax | -1.22M | -1.22M | -2.39M | -1.09M | -187.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.22M | -1.22M | -2.39M | -1.09M | -187.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.22M | -1.22M | -2.39M | -1.09M | -187.00K |
| EBIT | -1.45M | -1.45M | -1.72M | -1.04M | -1.54M |
| EBITDA | -1.45M | -1.45M | -1.72M | -1.03M | -1.50M |
| EPS Basic | -0.04 | -0.04 | -0.09 | -0.04 | -0.01 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.05 | -0.02 | 0.00 |
| EPS Diluted | -0.04 | -0.04 | -0.09 | -0.04 | -0.01 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.05 | -0.02 | 0.00 |
| Average Basic Shares Outstanding | 30.08M | 30.08M | 27.80M | 29.98M | 29.54M |
| Average Diluted Shares Outstanding | 30.08M | 30.08M | 27.80M | 29.98M | 29.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |